Enovis Corp(ENOV) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 5:57 PM ET (Korea 10/31 06:57)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -19.24 | Insider Own | 2.48% | Shs Outstand | 57.7M | Perf Week | -5.55% |
| Market Cap | 1.15B | Forward P/E | 5.62 | EPS next Y | -2.31% | Insider Trans | 1.96% | Shs Float | 56.2M | Perf Month | 10.3% |
| Enterprise Value | 2.51B | PEG | 0.94 | EPS next Q | 0.77 | Inst Own | 117.2% | Short Float | 20.81% | Perf Quarter | -36.63% |
| Income | -1.10B | P/S | 0.5 | EPS this Y | 9.91% | Inst Trans | -0.52% | Short Ratio | 7.63 | Perf Half Y | -15.71% |
| Sales | 2.30B | P/B | 0.78 | EPS next 5Y | 6% | ROA | -25.03% | Short Interest | 11.70M | Perf YTD | -25.26% |
| Book/sh | 25.61 | P/C | 91.42 | EPS past 3/5Y | -321.2% - | ROE | -54.25% | 52W High | -38.57% ($32.41) | Perf Year | -35.13% |
| Cash/sh | 0.22 | P/FCF | 18.04 | Sales past 3/5Y | 12.88% -6.05% | ROIC | -39.52% | 52W Low | 19.22% ($16.70) | Perf 3Y | -55.72% |
| Dividend Est. | - | EV/EBITDA | 6.7 | EPS Y/Y TTM | -30.14% | Gross Margin | 53.34% | Volatility(W/M) | 6.09% 4.99% | Perf 5Y | -77.57% |
| Dividend TTM | - | EV/Sales | 1.09 | Sales Y/Y TTM | 4.89% | Oper. Margin | 3.41% | ATR (14) | 1.08 | Perf 10Y | -63.45% |
| Dividend Ex-Date | - | Quick Ratio | 1 | EPS Q/Q | 96.78% | Profit Margin | -47.9% | RSI (14) | 48.28 | Recom | 1.23 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.98 | Sales Q/Q | 3.23% | SMA20 | 0.62% ($19.79) | Beta | 1.11 | Target Price | $36.08 |
| Payout | - | Debt/Eq | 0.93 | Earnings | 2026/11/5 | SMA50 | -0.48% ($20.01) | Rel Volume | 1.65 | Prev Close | $22.81 |
| Employees | 7802 | LT Debt/Eq | 0.88 | EPS/Sales Surpr. | 6.27% 0.16% | SMA200 | -13.71% ($23.07) | Avg Volume(3M) | 1.53M | Price | $19.91 |
| IPO | 2008/5/8 | Option/Short | Yes/Yes | Trades | 18937 | Volume | 2,524,794 | Change | -12.71% |
🦴 Enovis (ENOV) is a U.S. medical device company specializing in orthopedics. It offers a broad product portfolio covering the full recovery journey for patients, ranging from braces and pain management products designed to help prevent injuries and support rehabilitation, to reconstructive surgical implants such as artificial joints. Headquartered in the United States, the company supplies orthopedic solutions to global markets.
Over the past 1 year, on the lower side
39% below its 1-year high.
Traded more than usual. That is 165% of its average volume.
Next earnings report: November 5
5 days to go.
ENOV keeps an operating profit but posts a net loss
Of every $100 in sales, $3.41 is kept as operating profit.
Tap to view numbers
Growth is moderate
Earnings are expected to grow by +9.9% this year.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $50. Peers typically go for $326.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -77.6%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
20.8% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #35 of 142 in the industry
Based on market cap of $1B.
FAQ
What kind of company is ENOV?
ENOV belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of ENOV?
The market cap of ENOV is approximately $1.1B, ranking 2,471 within its sector.
What is the 52-week high and low for ENOV?
ENOV has recorded a 52-week high of $32.41 and a low of $16.70.
